Evolent Health Q3 net loss narrows 12% to $23.57 million; revenue rises 51% to $725.37 million
EVH•Evolent Health’s third-quarter 2026 net loss attributable to common shareholders narrowed 12% year over year to $23.57 million, while revenue rose 51% to $725.37 million. Full-year revenue guidance remained $2.6 billion to $2.7 billion.
1. Quarterly results and outlook
Evolent Health reported third-quarter 2026 revenue of $725.37 million, up 51% year over year, and a net loss attributable to common shareholders of $23.57 million, down 12%. The company kept its full-year 2026 revenue guidance at $2.6 billion to $2.7 billion. An expanded oncology agreement covers approximately 1 million additional Commercial lives, with services starting January 1, 2027.
